Abstract
Tucatinib is an oral, small molecule, selective HER2 inhibitor initially developed by Array BioPharma (a subsidiary of Pfizer) and subsequently develo......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
